Celltrio, a pioneering life sciences company delivering advanced automation solutions for cell culturing and cell & gene therapy, today announced the closing of a $15 million financial investment round led by Premier Partners, a leading investor in healthcare innovation.

Celltrio，一家为细胞培养和细胞与基因治疗提供先进自动化解决方案的先锋生命科学公司，今天宣布完成了由医疗保健创新领域领先投资者Premier Partners领投的1500万美元融资回合。

Celltrio designs and manufactures scalable cell culture automation platforms that integrate seamlessly into R&D and GMP environments. Its flagship RoboCell® system fully automates processes in sterile cell culturing, and cell and gene therapy, delivering high-throughput, consistent results for biopharma, cell therapy, and regenerative medicine labs..

Celltrio设计和制造可扩展的细胞培养自动化平台，这些平台可以无缝集成到研发和GMP环境中。其旗舰产品RoboCell®系统完全自动化了无菌细胞培养以及细胞和基因治疗的过程，为生物制药、细胞治疗和再生医学实验室提供高通量且一致的结果。